Chen Q, Xu F, Wu H, Xie L, Li H, Jiao C
Mol Neurobiol. 2025; .
PMID: 39934560
DOI: 10.1007/s12035-025-04752-5.
Mu J, Li R, Zheng Y, Lu Y, Ma L, Yin L
Stem Cell Res Ther. 2024; 15(1):296.
PMID: 39256886
PMC: 11389492.
DOI: 10.1186/s13287-024-03917-8.
Andryszak N, Kurzawa P, Krzyzaniak M, Ruchala M, Nowicki M, Izycki D
Sci Rep. 2024; 14(1):1969.
PMID: 38263416
PMC: 10805734.
DOI: 10.1038/s41598-024-51796-z.
Aiyappa-Maudsley R, McLoughlin L, Hughes T
Int J Mol Sci. 2023; 24(17).
PMID: 37685898
PMC: 10487980.
DOI: 10.3390/ijms241713093.
Yang H, Zhou Y, Wang L, Lv M, Sun J, Luo Z
Curr Mol Med. 2023; 24(7):931-939.
PMID: 37533240
DOI: 10.2174/1566524023666230801124826.
Advances in landscape and related therapeutic targets of the prostate tumor microenvironment.
Li D, Xu W, Chang Y, Xiao Y, He Y, Ren S
Acta Biochim Biophys Sin (Shanghai). 2023; 55(6):956-973.
PMID: 37294106
PMC: 10326416.
DOI: 10.3724/abbs.2023092.
Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
Liu F, Wang Z, Li X, Zhang Z, Yang Y, Chen J
Cancer Commun (Lond). 2022; 43(2):214-224.
PMID: 36528491
PMC: 9926960.
DOI: 10.1002/cac2.12396.
Association between SEMA3A signaling pathway genes and BMD/OP risk: An epidemiological and experimental study.
Zhou H, Wei M, Di D, Zhang R, Zhang J, Yuan T
Front Endocrinol (Lausanne). 2022; 13:1014431.
PMID: 36425469
PMC: 9679019.
DOI: 10.3389/fendo.2022.1014431.
The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors.
Palano M, Gallazzi M, Cucchiara M, Deho F, Capogrosso P, Bruno A
Explor Target Antitumor Ther. 2022; 3(5):694-718.
PMID: 36338516
PMC: 9630328.
DOI: 10.37349/etat.2022.00108.
The Roles of Tumor-Associated Macrophages in Prostate Cancer.
Han C, Deng Y, Xu W, Liu Z, Wang T, Wang S
J Oncol. 2022; 2022:8580043.
PMID: 36117852
PMC: 9473905.
DOI: 10.1155/2022/8580043.
Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling Interaction With FLNA.
Li Y, Xu C, Sun B, Zhong F, Cao M, Yang L
Front Oncol. 2022; 12:913498.
PMID: 35957887
PMC: 9358705.
DOI: 10.3389/fonc.2022.913498.
Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention.
Mirzaei S, Paskeh M, Okina E, Gholami M, Hushmandi K, Hashemi M
J Exp Clin Cancer Res. 2022; 41(1):214.
PMID: 35773731
PMC: 9248128.
DOI: 10.1186/s13046-022-02406-1.
The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death.
Wu L, Liu F, Yin L, Wang F, Shi H, Zhao Q
Cancer Commun (Lond). 2022; 42(8):768-783.
PMID: 35706368
PMC: 9395313.
DOI: 10.1002/cac2.12321.
Semaphorins as Potential Immune Therapeutic Targets for Cancer.
Jiang J, Zhang F, Wan Y, Fang K, Yan Z, Ren X
Front Oncol. 2022; 12:793805.
PMID: 35155237
PMC: 8830438.
DOI: 10.3389/fonc.2022.793805.
